Kadmon Holdings, Inc.
KDMN evidence brief
What we can confirm
- BioSniper Score:
- 6.4 / 10
- Lead Asset:
- belumosudil (BLA Filed)
What it means
What to watch
Prepared research question
What matters most for KDMN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Tracking 1 pipeline candidate for Kadmon Holdings, Inc..
Run Kadmon Holdings, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Kadmon Holdings, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: BLA Filed
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Governance
Frequently asked questions
What is Kadmon Holdings, Inc.'s lead drug candidate?
Kadmon Holdings, Inc.'s most advanced tracked candidate is belumosudil (BLA Filed) for chronic graft-versus-host disease (cGVHD).
Who is the CEO of Kadmon Holdings, Inc.?
New York April is the chief executive officer of Kadmon Holdings, Inc. (KDMN).
What therapeutic areas does Kadmon Holdings, Inc. focus on?
Kadmon Holdings, Inc. develops therapies across Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.